🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

💊❓Advanced NSCLC with driver mutation 👇 ➡️If no radiologically detectable disease after TKI and local consolidative therapy ➡️ Stop TKI❗️➡️ Follow-up➡️ Restart TKI if progressive disease, detectable ctDNA, or CEA elevation JAMA Oncology ✅mPFS: 18.4 mo ✅median treatment

It’s our launch day!! 🥳

new Science Magazine framework to improve cancer early detection: two injectable priming agents (nanoparticles & engineered antibodies) temporarily slow down the clearance of circulating tumor DNA from the body, allowing for higher detection sensitivity science.org/doi/10.1126/sc…

Mariposa trial - Just published Mathew Carter Philip Russell Igor The Christie NHS Division of Cancer Sciences Sharon 💙🐝🌹 BTOG nejm.org/doi/pdf/10.105…

Extravasation management of vesicant and irritant agents👇 OncoAlert

Wow! GLP-1 receptor agonists now linked to a substantial reduction in incidence for 10 types of cancers, in patients with Type 2 Diabetes !jamanetwork.com/journals/jaman…

HER2: a remarkable story of precision oncology. Check this wonderful Nature review on targeting HER2 beyond breast. 👉Important to remember: now that we have an agnostic anti-HER2 drug approved (T-DXd), every adv cancer patient should get HER2 testing! nature.com/articles/s4157…

Out now our review on #BispecificAntibodies Trends in Cancer!👉t.ly/L0BS0 We cover preclinical & clinical developments, trials data & challenges ahead A joy working w the dream team! Mercedes Herrera Giulia Pretelli Thiago M Steiner Lillian Siu @ElenaGarralda Jayesh Desai

The Lung Team at the Christie is currently recruiting in studies for patients with stage 4 ROS1+ NSCLC who have received at least one previous line of treatment. If interested, please email [email protected] BTOG The ROS1ders, Inc.

Distinct clinical outcomes & biological features of specific KRAS mutants in human pancreatic cancer Cancer Cell doi.org/10.1016/j.ccel… 👉KRASG12R enriched in early stage w/ reduced nodal disease + distant recurrence 👉improved OS 🧐 Supports KRAS mutational testing in #PDAC

Mariposa study. Congratulations to the authors Raffaele Califano and colleagues and all those who contributed Philip Russell. ESMO - Eur. Oncology Manchester Cancer Research Centre

ONLINE NOW: Cell-free and extrachromosomal DNA profiling of small cell lung cancer dlvr.it/TCpYBL

Dr Roya Behrouzi Trends in Molecular Medicine CRUK National Biomarker Centre CRUK Manchester Institute Division of Cancer Sciences UoM Biology, Medicine and Health Manchester Cancer Research Centre NIHR Manchester Biomedical Research Centre Cell Press IASLC EACR ESMO - Eur. Oncology BTOG Christie Library UoM Library Well done Dr Roya Behrouzi ! #cfDNA #liquidbiopsy #ecDNA #SCLC CRUK National Biomarker Centre

Please to share our work published in iScience journal comparing #cfDNA and small #extracellularvesicle DNA sequencing from the plasma of lung cancer patients. #liquidbiopsy cell.com/iscience/fullt… [cell.com]

In this new review, Dr. Dr Roya Behrouzi at The Christie NHS and team discuss how cell-free DNA profiling modalities can be harnessed to expand the clinical applications of liquid biopsy in small cell lung cancer. bit.ly/47rMJb0

Radiomics for early detection pneumonitis in PACIFIC: Jarushka Naidoo 👉 x4 variables, inc clinical data ✅ Identifies symptomatic pneumonitis: PPV 0.46, NPV 0.93 🤔 Can it detect baseline asymptomatic ILD, to ⬇️ risk of future treatment associated pneumonitis? #ESMO2024 #LCSM

Great to rejoin the Manchester Immuno-Oncology Network #MION 🐝 at the first seminar of the 2024-2025 academic year. Looking forward to many fruitful collaborations 🤝 between scientists & clinicians. Manchester Cancer Research Centre Excellent talks from Ik Shin Chin Evangelos Giampazolias @JonathanWorboys!

📰 #InTheNews A new drug combination trialled at The Christie stops advanced lung cancer with EGFR mutations from progressing for longer than the drug that's currently in use. More in the Guardian 👇 bit.ly/3YdMFIF

5-FU does not synergize with DNA-damaging agents such as oxaliplatin or irinotecan ⁦Cell Reports Medicine⁩ nature.us17.list-manage.com/track/click?u=…